HomeFinTechINOVIQ: Granted SubB2M US patent for diagnostic applications

INOVIQ: Granted SubB2M US patent for diagnostic applications

Date:

ABN AMRO-Owned Neobroker Fined $1.6M for Paying Finfluencers

A Significant Penalty in the Financial Industry Highlights Regulatory...

AvidXchange Explores Potential Sale Amid Market Changes

What Investors Need to Know About AvidXchange's Strategic Shift Highlights:...

Raisin Expands Its Offerings by Launching in Finland

Discover how Raisin is transforming the financial landscape in...

INOVIQ Granted SubB2M US patent for diagnostic applications

  • INOVIQ (IIQ) receives a US patent that covers its SubB2M technology and provides intellectual property protection in the US for diagnostic applications
  • The patent is titled “Subtilase cytotoxin B subunit mutant” and was issued to Griffith University and the University of Adelaide
  • The SubB2M technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc which is found in multiple human cancers
  • The patent is titled “Subtilase cytotoxin B subunit mutant” and was issued to Griffith University and the University of Adelaide
  • Shares in the company are up 14.1 per cent, trading at 44.5 cents as of 10:45 am AEST
Exit mobile version